摘要
目的探讨五禽汤治疗Ⅲa型慢性前列腺炎的临床疗效。方法采用双盲法将234例Ⅲa前列腺炎患者随机分为治疗组(五禽汤组)和对照组(可多华组),疗程为1个半月,观察治疗前后前列腺液白细胞计数(EPS-WBC)、pH值、疼痛症状评分(PS)、排尿症状评分(USS)、生活质量评分(QLS)、最大尿流率(MFR)、平均尿流率(AFR)。结果经Ridit分析,治疗组临床疗效明显优于对照组(P<0.01),EPS-WBC,MFR,AFR的恢复情况亦明显优于对照组(P<0.01),NIH-CPSI总评分降低幅度高于对照组(P<0.01)。结论五禽汤治疗Ⅲa型慢性前列腺炎疗效较好且副作用小,具有临床推广价值。
Objective To discuss the clinical treatment effect of Ⅲa type chronic prostatitis treated with Wuqin decoction, Methods Double blind method was adopted to divide 234 cases of Ⅲa type chronic prostatitis randomly into the treatment （Wuqin decoction）group and the control （cardura XL） group. The treatment course was one and a half month. The white blood cell count of prostatic fluid （EPS-WBC）, pH value, pain scoring （PS）, urination symptom scoring （USS）, life quality scoring （QLS）, maximum uroflow rate （MFR） and average flow rate （AFR） before and after treatment were all observed and evaluated. Results The treatment effect of the treatment group was obviously better than that of the control group （ P 〈 0. 01 ） by Ridit analysis. The recovery of EPS - WBC, MFR and AFR of the treatment group were also obviously better than that of the control group （P 〈 0.01 ）. The reduction of general NIH- CPSI scoring was higher than that of the control group （ P 〈 0. 01 ）. Conclusion Wuqin decoction has good treatment effect for Ⅲ a type chronic prostatitis with minor adverse reactions so that it is worthy of being developed clinically.
出处
《中国药业》
CAS
2007年第13期40-41,共2页
China Pharmaceuticals
